Hepregen

About:

Hepregen Corporation is a biotechnology company that focuses on understanding the metabolism of drugs in the liver.

Website: http://www.hepregen.com

Twitter/X: HepregenCorp

Top Investors: National Science Foundation, Massachusetts Life Sciences Center, Battelle Ventures, Innovation Valley Partners

Description:

Hepregen Corporation is pursuing applications of its microliver platform for acute and chronic toxicity as well as for understanding the metabolism of drugs in the liver. Applications in the pharmaceutical industry may well extend beyond toxicity and metabolism to include utility in drug discovery, disease modeling (obesity, infectious disease, diabetes), in silico models, and toxicogenomics. Hepregen is actively engaged in industrial collaborations to validate the microliver platform in a wide spectrum of applications. The combined markets for Hepregen's microliver platform is approximately a billion dollars annually.

Total Funding Amount:

$4.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Medford, Massachusetts, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)hepregen.com

Founders:

Bonnie Fendrock, Salman Khetani, Sangeeta Bhatia

Number of Employees:

11-50

Last Funding Date:

2012-06-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai